| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | L1R |
| Uniprot No | P20540 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-183aa |
| 氨基酸序列 | GAAASIQTTVNTLSERISSKLEQEANASAQTKCDIEIGNFYIRQNHGCNLTVKNMCSADADAQLDAVLSAATETYSGLTPEQKAYVPAMFTAALNIQTSVNTVVRDFENYVKQTCNSSAVVDNKLKIQNVIIDECYGAPGSPTNLEFINTGSSKGNCAIKALMQLTTKATTQIAPRQVAGTG |
| 预测分子量 | 21.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于L1R重组蛋白的3篇模拟参考文献及其摘要概括，供参考：
---
1. **文献名称**：Structural and Functional Analysis of the Vaccinia Virus L1R Recombinant Protein
**作者**：Smith J, et al.
**摘要**：本研究解析了痘病毒L1R重组蛋白的晶体结构，揭示了其与宿主细胞膜相互作用的分子机制，为开发靶向病毒进入的抑制剂提供了结构基础。
---
2. **文献名称**：L1R Recombinant Protein as a Subunit Vaccine Candidate Against Poxviruses
**作者**：Li X, et al.
**摘要**：通过在大肠杆菌中表达纯化L1R重组蛋白，验证其在小鼠模型中诱导中和抗体的能力，证明其作为新型亚单位疫苗的潜在应用价值。
---
3. **文献名称**：High-Yield Expression and Immunogenicity of L1R Protein in Mammalian Cells
**作者**：Garcia R, et al.
**摘要**：优化了哺乳动物细胞表达系统中L1R重组蛋白的生产工艺，证实其糖基化修饰对增强免疫原性的重要性，为规模化制备奠定了基础。
---
(注：上述文献为模拟示例，实际研究中建议通过PubMed或Web of Science检索具体文献。)
**Background of L1R Recombinant Protein**
The L1R recombinant protein is derived from the L1R gene of orthopoxviruses, notably the vaccinia virus (VACV), a member of the *Poxviridae* family. Orthopoxviruses are large, double-stranded DNA viruses, with VACV serving as a prototype for studying poxvirus biology due to its historical role in smallpox vaccination. The L1R gene encodes a conserved viral envelope protein critical for viral entry and infectivity.
Structurally, the L1R protein is a 27-29 kDa transmembrane glycoprotein localized on the mature virion (MV) surface. It plays a pivotal role in mediating viral attachment and membrane fusion during host cell entry. L1R interacts with other viral entry-fusion complex (EFC) components, such as A28 and H2. forming a multiprotein structure essential for initiating infection. Its neutralizing epitopes make it a key target for antibody-mediated immune responses.
Recombinant L1R is produced via genetic engineering, often expressed in *E. coli* or mammalian systems to ensure proper folding and post-translational modifications. Purified L1R retains antigenic properties, enabling its use in immunological studies, vaccine development, and diagnostic tools. Notably, it has been explored as a component of subunit vaccines against smallpox and related orthopoxviruses, offering a safer alternative to live-virus vaccines.
Research on L1R also sheds light on viral entry mechanisms, aiding the design of antiviral inhibitors. Its conserved nature across orthopoxviruses underscores its functional importance and utility as a cross-protective antigen. Overall, L1R recombinant protein serves as a vital tool in virology, vaccinology, and therapeutic development against poxvirus infections.
×
